Amneal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AMRX and other ETFs, options, and stocks.

About AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. 

CEO
Chintu Patel
CEOChintu Patel
Employees
8,300
Employees8,300
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
2002
Founded2002
Employees
8,300
Employees8,300

AMRX Key Statistics

Market cap
3.83B
Market cap3.83B
Price-Earnings ratio
840.85
Price-Earnings ratio840.85
Dividend yield
Dividend yield
Average volume
1.92M
Average volume1.92M
High today
$12.22
High today$12.22
Low today
$11.90
Low today$11.90
Open price
$12.01
Open price$12.01
Volume
2.36M
Volume2.36M
52 Week high
$12.68
52 Week high$12.68
52 Week low
$6.69
52 Week low$6.69

Stock Snapshot

The current Amneal Pharmaceuticals(AMRX) stock price is $12.18, with a market capitalization of 3.83B. The stock trades at a price-to-earnings (P/E) ratio of 840.85.

During the trading session on 2025-12-06, Amneal Pharmaceuticals(AMRX) shares reached a daily high of $12.22 and a low of $11.90. At a current price of $12.18, the stock is +2.4% higher than the low and still -0.3% under the high.

Trading volume for Amneal Pharmaceuticals(AMRX) stock has reached 2.36M, versus its average volume of 1.92M.

Over the past 52 weeks, Amneal Pharmaceuticals(AMRX) stock has traded between a high of $12.68 and a low of $6.69.

Over the past 52 weeks, Amneal Pharmaceuticals(AMRX) stock has traded between a high of $12.68 and a low of $6.69.

AMRX News

TipRanks 22h
Amneal Pharmaceuticals announces results from Phase 4 ELEVATE-PD

Amneal Pharmaceuticals (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the Parkinson’s Study Group, PSG, A...

Simply Wall St 1d
A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects

Amneal Pharmaceuticals (AMRX) just picked up two meaningful FDA wins, securing approvals for generic versions of Restasis and ProAir HFA that open doors into mu...

A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects
Simply Wall St 4d
FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals

Amneal Pharmaceuticals recently received U.S. FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a preservative-free generic of RESTASIS, to treat dry...

FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals

More AMRX News

Simply Wall St 6d
Amneal Pharmaceuticals, Inc.'s Price Is Right But Growth Is Lacking After Shares Rocket 25%

Despite an already strong run, Amneal Pharmaceuticals, Inc. ( ) shares have been powering on, with a gain of 25% in the last thirty days. Looking back a bit fur...

Amneal Pharmaceuticals, Inc.'s Price Is Right But Growth Is Lacking After Shares Rocket 25%

People also own

Based on the portfolios of people who own AMRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.